Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced the pricing of a firm ...
Teoxane's proposal provides a 16% premium over the $3.10 per share price in Revance's amended and restated merger agreement with Crown Laboratories, Inc. ("Crown"), as announced on December 9, 2024.
MicroStrategy Inc. unveiled its latest capital raise late Friday with news of plans to issue $2 billion in preferred stock to raise the funds needed to buy more bitcoin.
MicroStrategy is targeting a capital raise of up to $2 billion to continue to strengthen its balance sheet and acquire more the business software company announced. The capital raise will be through ...